tbuckley/cabot-search huggingface dataset:
AB0524 Incidence and Risk Analysis of Osteomyelitis in Systemic Lupus Erythematosus Patients: A Nationwide Cohort Study: Table 1.
Authors: Y.F. Huang, C.C. Lai
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Fever and musculoskeletal pain are manifestations of systemic lupus erythematosus (SLE). These symptoms might be confused with the presentations of osteomyelitis, especially in SLE patients. On the other hand, SLE patients may have higher risk to get infection, including osteomyelitis, due to immunodeficiency. <h3>Objectives</h3> This study aimed to investigate the epidemiology and risk factors of osteomyelitis in SLE patients. <h3>Methods</h3> We conducted this population-based cohort in entire Taiwanese by using Taiwan National Health Insurance Research Database. Patients with SLE and age- and sex-matched control group without SLE were enrolled. The primary endpoint was the first occurrence of osteomyelitis. The risks of osteomyelitis in SLE patients were analyzed with Cox proportional hazards regression models, including age, sex, comorbidities and medications. <h3>Results</h3> From 2000 to 2012, we identified 18472 SLE patients (88.6% women, mean age of 37.5 years) and 73888 control patients. Compared with the controls, the osteomyelitis incidence rate ratio (IRR) (95% CIs) among all SLE patients were 8.23 (6.76–10.05). The IRR between young SLE patients (18–40 years) and their controls was 22.87 (15.59–34.44). Multivariable Cox regression analyses in SLE patients indicated that older age, being male, with disease of peripheral artery disease (PAOD), chronic kidney disease (CKD), bone fracture, performing orthopedic surgery in recent 6 months, and daily prednisolone equivalent to or more than 7.5 mg are strongly related to osteomyelitis. In contrast, the use of hydroxychloroquine was a protective factor for osteomyelitis. <h3>Conclusions</h3> SLE patients had a higher incidence rate of osteomyelitis, especially those who were older, male, had history of PAOD, CKD, bone fracture and orthopedic surgery and used a high dose of corticosteroid. <h3>References</h3> Wu, K.C., et al., Osteomyelitis in patients with systemic lupus erythematosus. J Rheumatol, 2004. 31(7): p. 1340–3. Danza, A. and G. Ruiz-Irastorza, Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus, 2013. 22(12): p. 1286–94. <h3>Disclosure of Interest</h3> None declared
An Impdh Inhibitor, FF-10501 Possesses Activating Effects on Myeloid Differentiation As Well As Anti-Proliferation
Authors: Michiko Ichii, Motohiko Murase, Kensuke Komatsu, Motoki Saito, Jun Toda, Kenji Oritani, Hiroyuki Iwamura, Yuzuru Kanakura
Journal: Blood (2015)
Motexafin Gadolinium (MGD) Induces Oxidant Stress and Downregulates Both Pro and Anti-Oxidant Genes in the Ramos Lymphoma Cell Line: Signaling through p53 Mediated Pathways.
Authors: Amareshwar T.K. Singh, Andrew M. Evens, Qudsia Haque, Sheila N. Prachand, Karthik T.K. Singh, Leo I. Gordon
Journal: Blood (2007)
Arginase and YKL-40, Effectors of Immunosuppressive Myeloid Cells, Are Over-Expressed In the Bone Marrow of Most Chronic Myelomonocytic Leukemia Patients, and Are Potential Prognostic Biomarkers In Myelodysplastic Syndrome
Authors: Michael J. Rauh, Deeksha Mahendru, Roman Shapiro, Alden Chesney, David Good, Marciano D. Reis, Adam Lam, Gerald Krystal, Rena Buckstein, Richard A. Wells
Journal: Blood (2010)
PWE-056 Urinary Metabolomic Profiling in Patients with Ulcerative Colitis (UC)
Authors: D Watson, DR Gaya, IA Alothaim
Journal: Gut (2016)

<h3>Introduction</h3> Metabolomic profiling is a technique which can be used for the discovery of biomarkers which could be used for the non-invasive diagnosis and monitoring of disease by sampling bodily fluids. We investigated urinary metabolomic profiles of patients with active UC, quiescent UC and controls with IBS attending the GI clinic at Glasgow Royal Infirmary. <h3>Methods</h3> After obtaining written informed consent, urine samples were collected from 51 patients attending the GI clinic with a confirmed diagnosis of either active UC (12), quiescent UC (26) controls with IBS (14). The samples were analysed by liquid chromatography interfaced with an Orbitrap mass spectrometer. The data generated were modelled by using Simca P 14. <h3>Results</h3> Figure 1 shows comparison of profiles from 12 patients with active UC in comparison with 14 controls based on ten metabolites listed in table 1 with their <i>p</i> values and ratios. <b>Figure 1 </b>Orthogonal partial least squares discriminant analysis model comparing patients with active IBD (AM) and controls (CF). R<sup>2</sup>X(cum) 0.985, R<sup>2</sup>Y (cum) 0.889, Q<sup>2</sup> (cum) 0.782. <b>Table 1</b> Markers used in the model (Figure 1) separating controls and active UC. <h3>Conclusion</h3> Separation between active UC and control samples is clear based on ten metabolites. N-methyl histidine has been observed as a marker of increased protein turnover in IBD<sup>1</sup> and is elevated in active UC samples in the current dataset along with its metabolite N-methylimidazolone acetate. Glutamine is higher in the IBD samples and is essential for the preservation of gut integrity,<sup>2</sup> although how this relates to elevated levels of glutamine in urine is not clear. In addition levels of rhamnose, arabinoate and mannonate which are derived from dietary fibre are altered. Overall there are strong indicators of metabolic changes in the urine of patients with active UC. Some of the putative markers e.g. glutamine are relatively abundant and may be suitable for a simple urinary test. The next stage will be to quantify these markers, validate the findings in a larger cohort and to determine whether they are also present in saliva (also collected from this cohort). <h3>Disclosure of Interest</h3> None Declared
SAT0119 Comparison between Carotid Plaque and Carotid Intima Media Thickness To Detect Subclinical Atherosclerosis in Rheumatoid Arthritis: Table 1
Authors: L. Riancho-Zarrabeitia, A. Corrales, M. Santos-Gόmez, V. Portilla, R. Blanco, P. Dessein, M.A. González-Gay
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Carotid plaque (CP) detected by ultrasonography and carotid intima-media thickness (cIMT) are useful surrogate markers for subclinical atherosclerosis and good predictors of cardiovascular disease in the general population and rheumatoid arthritis (RA). <h3>Objectives</h3> Our aim was to determine if cIMT may predict the presence of carotid plaques. <h3>Methods</h3> We evaluated 670 RA patients from NW Spain without previous history cardiovascular events. Carotid ultrasonography was performed by a MyLab 70 scanner (Esaote; Genoa, Italy), equipped with 7–12 MHz linear transducer and the <i>automated software guided technique radiofrequency</i> – <i>Quality Intima Media Thickness</i> in <i>real</i>-<i>time</i> (<i>QIMT</i>, <i>Esaote</i>, <i>Maastricht</i>, <i>Holland</i>). The cIMT was determined as the average of three measurements in each common carotid artery. The final cIMT was the largest average cIMT (left or right). Carotid plaque was defined according to the Manheim Consensus Conference criteria. Based on studies reported in non-rheumatic patients, a cIMT was considered as associated with high cardiovascular risk if it was ≥0.90 mm. <h3>Results</h3> Unilateral and bilateral carotid plaque frequency and cIMT values are summarized in table 1. cIMT values were 0.619±0.105 mm in patients without plaques and 0.774 ± 0.161 mm in those with plaques (p&lt;0.001). Using 0.90 mm as the cIMT cut-off value for high cardiovascular risk, the sensitivity to detect carotid plaques was 21.2% and the specificity 99%. A ROC curve comparing the presence of carotid plaque and cIMT was performed, being the area under the curve 0.795. The best cIMT cut-off point to determine the presence of plaques was considered as the one with the highest sensitivity and specificity. According to that, 0.670 mm was found to be the best cut-off point, being sensitivity and specificity for plaque detection 71.9% and 74% respectively. Positive predictive value for a cIMT ≥0.670 mm was 78.3% in our population, being 66.8% the negative predictive value. Regarding bilateral plaques, a cIMT cut-off value of 0.90 mm had sensitivity of 27.7% and specificity of 96.6%. The ROC curve showed that the best cut-off point for bilateral plaque detection was also 0.670 mm with sensitivity 79.1% and specificity 64.2%. <h3>Conclusions</h3> In Spanish RA patients cIMT ≥0.670 mm is a good predictor of carotid plaques. Our study suggests the possibility of considering a cIMT lower than 0.90 mm as a predictor of high cardiovascular risk in RA. <h3>Disclosure of Interest</h3> None declared
Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia
Authors: C Dafflon, V J Craig, H Méreau, J Gräsel, B Schacher Engstler, G Hoffman, F Nigsch, S Gaulis, L Barys, M Ito, J Aguadé-Gorgorió, B Bornhauser, J-P Bourquin, A Proske, C Stork-Fux, M Murakami, W R Sellers, F Hofmann, J Schwaller, R Tiedt
Journal: Leukemia (2016)
Impact of the Donor Recipient Sex Combination in Hematopoietic Stem Cell Transplantation: H-Y as a Model for the Interaction between Major and Minor Histocompatibility Antigens.
Authors: Alois Gratwohl, Martin Stern, Ronald Brand, Theo de Witte, Anna Sureda, Vanderson Rocha, Jakob Passweg, Helen Baldomero, Dietger Niederwieser
Journal: Blood (2007)
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
Authors: Désirée van der Heijde, Atul Deodhar, James C Wei, Edit Drescher, Dona Fleishaker, Thijs Hendrikx, David Li, Sujatha Menon, Keith S Kanik
Journal: Annals of the Rheumatic Diseases (2017)

Objectives To compare efficacy and safety of various doses of tofacitinib, an oral Janus kinase inhibitor, with placebo in patients with active ankylosing spondylitis (AS, radiographic axial spondyloarthritis). Methods In this 16-week (12-week treatment, 4-week washout), phase II, multicentre, dose-ranging trial, adult patients with active AS were randomised (N=51, 52, 52, 52, respectively) to placebo or tofacitinib 2, 5 or 10 mg twice daily. The primary efficacy endpoint was Assessment of SpondyloArthritis International Society 20% improvement (ASAS20) response rate at week 12. Secondary endpoints included objective measures of disease activity, patient-reported outcomes and MRI of sacroiliac joints and spine. Safety was monitored. Results Emax model analysis of the primary endpoint predicted a tofacitinib 10 mg twice daily ASAS20 response rate of 67.4%, 27.3% higher than placebo. Supportive normal approximation analysis demonstrated tofacitinib 5 mg twice daily ASAS20 response rate significantly higher than placebo (80.8% vs 41.2%; p&lt;0.001); tofacitinib 2 and 10 mg twice daily demonstrated greater response rate than placebo (51.9% and 55.8%, respectively; not significant). Secondary endpoints generally demonstrated greater improvements with tofacitinib 5 and 10 mg twice daily than placebo. Objective (including MRI) endpoints demonstrated clear dose response. Adverse events were similar across treatment groups with no unexpected safety findings. Dose-dependent laboratory outcome changes returned close to baseline by week 16. Conclusions Tofacitinib 5 and 10 mg twice daily demonstrated greater clinical efficacy versus placebo in reducing signs, symptoms and objective endpoints of active AS in adult patients with a similar 12-week safety profile as reported in other indications. Trial registration number NCT01786668 .
OP0143 The Effect of Physical Activity on The Risk of Total Joint Replacement for Severe Knee or Hip Osteoarthritis: A Population-Based Prospective Cohort Study
Authors: D. Aitken, I. Munugoda, F. Cicuttini, M. Callisaya, G. Jones
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Studies examining physical activity and joint health are conflicting – with some showing a detrimental effect and others showing either no effect or a beneficial effect. <h3>Objectives</h3> To explore the association between physical activity and knee or hip osteoarthritis leading to knee or hip joint replacement surgery. <h3>Methods</h3> 536 community-dwelling adults aged 51–79 years were assessed at baseline, 2.7, 5 and 10 years. Physical activity was measured by pedometer (steps/day). The incidence of knee or hip replacement surgery was reported at each follow-up. Log-binomial regression was used to examine the association between steps/day with incident knee and hip replacement adjusted for age, sex, BMI, x-ray disease severity, and pain. <h3>Results</h3> Over 10 years, 36 participants reported having a knee replacement and 27 reported having a hip replacement. For every 1000 steps/day increase at baseline, there was a 0.84 times (95% CI 0.72 to 0.99) lower risk of hip replacement (P=0.036). There was no significant association between steps/day and knee replacement (RR 1.00 95% CI 0.9999 to 1.00, P=0.778). Baseline BMI significantly predicted knee replacement (RR per SD increase in BMI 1.42 (95% CI 1.03 to 1.97, P=0.032)) but not hip replacement (RR 1.00 95% CI 0.91 to 1.10, P=0.984). <h3>Conclusions</h3> Higher physical activity levels were protective against hip replacement while being overweight or obese increased the risk for knee replacement. This suggests different causal pathways for each site with regard to habitual activity and body composition. <h3>Disclosure of Interest</h3> None declared
SB1317, a Potent and Orally Active FLT3-CDK Inhibitor with High Anti-Tumor Efficacy in Models of Hematological Malignancies.
Authors: Kee C. Goh, Wai C. Ong, Changyong Hu, Ai L. Liang, Walter Stunkel, Yong C. Tan, Kanda Sangthongpitag, Siok K. Goh, Zahid Q. Bonday, Anthony D. William, Brian W. Dymock, Ethirajulu Kantharaj, Jeanette M. Wood
Journal: Blood (2007)
IFN-α/IFN-λ responses to respiratory viruses in paediatric asthma
Authors: Annika Bergauer, Nina Sopel, Bettina Kroß, Tytti Vuorinen, Paraskevi Xepapadaki, Scott T. Weiss, Ashley Blau, Himanshu Sharma, Cornelia Kraus, Rebekka Springel, Manfred Rauh, Susanne Mittler, Anna Graser, Theodor Zimmermann, Volker O. Melichar, Alexander Kiefer, Marek L. Kowalski, Anna Sobanska, Tuomas Jartti, Heikki Lukkarinen, Nikolaos G. Papadopoulos, Susetta Finotto
Journal: European Respiratory Journal (2016)

We analysed the influence of rhinovirus (RV) in nasopharyngeal fluid (NPF) on type I and III interferon (IFN) responses ( e.g. IFN-α and IFN - λ) and their signal transduction, at baseline and during disease exacerbation, in cohorts of pre-school children with and without asthma. At the time of recruitment into the Europe-wide study PreDicta, and during symptoms, NPF was collected and the local RV colonisation was analysed. Peripheral blood mononuclear cells (PBMCs) were challenged in vitro with RV or not. RNA was analysed by quantitative real-time PCR and gene arrays. Serum was analysed with ELISA for IFNs and C-reactive protein. We found that PBMCs from asthmatic children infected in vitro with the RV1b serotype upregulated MYD88 , IRF1 , STAT1 and STAT2 mRNA, whereas MYD88 , IRF1 , STAT1 and IRF9 were predominantly induced in control children. Moreover, during symptomatic visits because of disease exacerbation associated with RV detection in NPF, IFN-α production was found increased, while IFN-λ secretion was already induced by RV in asthmatic children at baseline. During asthma exacerbations associated with RV, asthmatic children can induce IFN-α secretion, indicating a hyperactive immune response to repeated respiratory virus infection.
AB0278 Are There Differences in Basal Comorbidities between Rheumatoid Arthritis Patients Treated with Abatacept and Those Treated with Tumor Necrosis Factor Inhibitors?: Table 1
Authors: M.V. Hernández, C.A. Sánchez-Piedra, J.E. Inciarte-Mundo, F. Sánchez-Alonso, F.J. Manero-Ruiz, E. Cuende, R. Rosellό Pardo, E. Pérez-Pampín, C. Rodríguez-Lozano, P. Vela-Casasempere, C. Diaz-Torne, R. Sanmartí, J.J. Gόmez-Reino
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) patients frequently report concomitant comorbidities that could worsen their prognosis. Tumour necrosis factor inhibitors (TNFi), the most common biological agents used, have shown efficacy in RA patients, although use in RA patients with certain comorbidities warrant caution (1). Abatacept, a biologic agent with a different mechanism of action, inhibiting the co-stimulation of T-lymphocyte, has demonstrated differentiated safety profile (2), that could influence the biological agent prescribed in RA patients with some associated comorbidities <h3>Objectives</h3> To analyse differences in the frequency of baseline comorbidities in RA patients treated with abatacept compared with those treated with TNFi <h3>Methods</h3> Patients with RA recruited into the BIOBADASER 2.0 register from January 2008 to December 2014 and treated with abatacept or TNFi with comorbidities were selected. Comorbidity was defined as ≥1 of the following at initiation of biological therapy: ischemic heart disease; malignancy (except lymphoma); diabetes; chronic pulmonary obstructive disease (CPOD); smoking; hypercholesterolemia; hypertension; heart failure; renal failure; lymphoma; osteoporosis; Epstein Barr, hepatitis B or C virus infection; and others. We analysed the frequency of each comorbidity, and differences in the rate of baseline comorbidities in the two groups were compared using t-test <h3>Results</h3> From January 2008 to December 2014, 640 and 252 RA patients treated respectively with TNFi or abatacept were included in the BIOBADASER 2.0 register, of whom 51.6% had ≥1 comorbidity at baseline. Frequencies for every basal comorbidity described are shown in Table 1. There was a significantly higher rate of heart failure in abatacept than in TNFi patients. Other comorbidities showed no significant differences. <h3>Conclusions</h3> RA patients treated with abatacept had a higher baseline rate of concomitant heart failure compared with patients treated with TNFi, probably reflecting different recommendations on biological use. Even though abatacept has demonstrated a differentiated safety profile, overall no differences in other baseline comorbidities were found between groups <h3>References</h3> Singh et al. Arthritis Rheum 2016;68:1–26. Singh et al. Cochrane Database Syst Rev. 2011;16:CD008794 <h3>Disclosure of Interest</h3> None declared
Evaluation of vitamin status in patients with pulmonary tuberculosis
Authors: Jongwon Oh, Rihwa Choi, Hyung-Doo Park, Hyun Lee, Byeong-Ho Jeong, Hye Yun Park, Kyeongman Jeon, O Jung Kwon, Won-Jung Koh, Soo-Youn Lee
Journal: Journal of Infection (2016)
PTH-127 Endoscopic Variceal Band Ligation (EVBL) at The 37 Military Hospital, Accra-Ghana: Our Experience with The Euro-Ligator-Universal (Euro Multiband Ligator)
Authors: R Robinson, M Thomas, M Norwood, A Ntiri, K-U Lat, J Kpodo, E Asumanu, W Yevudza, N Nuamah
Journal: Gut (2016)

<h3>Introduction</h3> Bleeding gastro-eosophageal varices are the 3 rd commonest cause of UGI bleeding in Ghana and have a high mortality. EVBL is an effective, safe treatment for oesophageal varices but single use, preloaded ligators are unaffordable in developing countries. We report our early experience of the re-usable Euro-Ligator for variceal banding. <h3>Methods</h3> The Euro-Ligator is the first re-usable multiple band ligator. It operates on a different principle to other ligators. A rotating driver is locked into the instrument channel and pre-loaded bands are deployed as an inner cylinder is withdrawn. Training in the use of the Euro-Ligator was provided by a visiting team from the University Hospitals of Leicester, funded by the British Society of Gastroenterology. During a one day course (October ‘15) the endoscopy team at 37 Military received instruction in loading the bands, intubation, band deployment and disinfection. An instruction video of each step was produced. During the course 5 patients were successfully banded under the supervision of the visiting team. Dedicated lists for variceal banding were established. <h3>Results</h3> To date, 15 EVBL sessions have been performed on 7 patients (6 males, age range 16 to 62). In all, 60 bands have been deployed with a successful band deployment rate of 55/60 (91.6%). The mean number of bands used per session was 3.7. All procedures were elective day cases after an index bleed &amp; performed under conscious sedation. No mortality was recorded during the procedures &amp; all patients were discharged home the same day. We have not seen deep ulceration, perforation or aspiration pneumonia. One patient was lost to follow up after the index procedure and 1 patient died 2 weeks after the initial session from Hepatic Failure (Child Pugh C). In the remaining 5 patients under follow-up, haemostatic control has been achieved with no further bleeding episodes reported. Complete eradication has now been achieved in 1 patient. <h3>Conclusion</h3> This preliminary case report gives us some insight and working experience into the use of the multiband Euro-Ligator. We found the equipment easy to use and technically effective in the endoscopic treatment of oesophageal varices. We need to adhere to stringent disinfection and cleaning protocols to ensure long term safety in our patients and evaluate the clinical and cost effectiveness over a longer period. However, the Euroligator is a major advance in the management of bleeding oesophageal varices in the developing world <h3>Disclosure of Interest</h3> None Declared
Efficacy and tolerability of oxycodone-naloxone prolonged release tablets (o/n –prt) for moderate to severe bone pain in cancer patients (pts) bone metastases (bm): data from a single-centre experience
Authors: P.T. Falbo, A. Rozzi, M. Nappa, A.M. Costa, B. Spigone, G. Lanzetta
Journal: Annals of Oncology (2015)
IAP antagonists induce anti-tumor immunity in multiple myeloma
Authors: Marta Chesi, Noweeda N Mirza, Victoria M Garbitt, Meaghen E Sharik, Amylou C Dueck, Yan W Asmann, Ilseyar Akhmetzyanova, Heidi E Kosiorek, Arianna Calcinotto, Daniel L Riggs, Niamh Keane, Gregory J Ahmann, Kevin M Morrison, Rafael Fonseca, Martha Q Lacy, David Dingli, Shaji K Kumar, Sikander Ailawadhi, Angela Dispenzieri, Francis Buadi, Morie A Gertz, Craig B Reeder, Yi Lin, Asher A Chanan-Khan, A Keith Stewart, David Fooksman, P Leif Bergsagel
Journal: Nature Medicine (2016)
Efficacy and Safety of Yttrium-90 Ibritumomab Tiuxetan in Older Patients with Indolent Non-Hodgkin Lymphoma.
Authors: Silvana Capalbo, Gaetano Palumbo, Matteo Dell'Olio, Maria Grazia Franzese, Attilio Guarini, Nicola Di Renzo, Giuseppina Spinosa, Angela Lapietra, Elsa Pennese V, Nicola Cascavilla
Journal: Blood (2009)
Allogeneic Hematopoietic Stem Cell Transplantation after Combination Therapy with Imatinib and Intensive Chemotherapy for Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia.
Authors: Noriko Usui, Shingo Yano, Shinobu Takahara, Osamu Asai, Nobuaki Dobashi, Hiroshi Osawa, Yutaka Takei, Yoji Ogasawara, Hiroko Otubo, Yuko Yamaguchi, Takeshi Saito, Jiro Minami, Ken Kaito, Masayuki Kobayashi
Journal: Blood (2005)